Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Latest book
| LQDA - Liquidia | 17.67% | Reduce −3.8% | 2,447,500 | $79.73 | $195M | −97,500 | +$106M |
| ETON - Eton Pharmaceuticals | 9.38% | Hold | 2,860,000 | $36.20 | $104M | — | — |
| HROW - Harrow | 9.23% | Reduce −15.3% | 2,400,000 | $42.47 | $102M | −432,230 | +$2M |
| IRON - Disc Medicine | 5.66% | Add +103.1% | 855,000 | $73.14 | $63M | +434,000 | +$36M |
| URGN - Urogen Pharma | 4.80% | Add +0.7% | 1,439,996 | $36.80 | $53M | +9,996 | +$27M |
| APGE - Apogee Therapeutics | 4.69% | Hold | 390,000 | $132.73 | $52M | — | — |
| MGTX - Meiragtx | 4.34% | Add +67.2% | 3,550,000 | $13.51 | $48M | +1,426,741 | +$30M |
| SLGL - Sol-Gel Technologies | 3.36% | Hold | 500,000 | $74.14 | $37M | — | — |
| RZLT - Rezolute | 2.97% | Hold | 6,300,000 | $5.20 | $33M | — | — |
| TGTX - Tg Therapeutics | 2.66% | Hold | 535,000 | $54.94 | $29M | — | — |
| IMMX - Immix Biopharma | 2.19% | New | 2,345,000 | $10.31 | $24M | +2,345,000 | +$24M |
| CBIO - Crescent Biopharma | 2.15% | Add +0.5% | 1,319,351 | $18.00 | $24M | +6,736 | −$364K |
| STOK - Stoke Therapeutics | 2.07% | Hold | 700,000 | $32.72 | $23M | — | — |
| ACOG - Alpha Cognition | 1.89% | Add +13.0% | 2,895,467 | $7.22 | $21M | +333,517 | +$7M |
| EWTX - Edgewise Therapeutics | 1.84% | Hold | 500,000 | $40.63 | $20M | — | — |
| RVMD - Revolution Medicines | 1.70% | Hold | 100,000 | $187.28 | $19M | — | — |
| GLUE - Monte Rosa Therapeutics | 1.63% | New | 745,000 | $24.20 | $18M | +745,000 | +$18M |
| ALMS - Alumis | 1.40% | Hold | 550,000 | $28.14 | $15M | — | — |
| CDXS - Codexis | 1.39% | Hold | 6,785,000 | $2.26 | $15M | — | — |
| REPL - Replimune Group | 1.39% | New | 1,384,993 | $11.07 | $15M | +1,384,993 | +$15M |
| XOMA - Xoma Royalty | 1.30% | Add +12.8% | 338,374 | $42.50 | $14M | +38,374 | +$5M |
| MBX - Mbx Biosciences | 1.30% | Hold | 260,000 | $55.20 | $14M | — | — |
| RYTM - Rhythm Pharmaceuticals | 1.23% | Reduce −0.4% | 122,500 | $111.03 | $14M | −500 | −$22M |
| EDIT - Editas Medicine | 1.13% | Add +100.4% | 3,861,930 | $3.24 | $13M | +1,934,933 | +$8M |
| PTGX - Protagonist Therapeutics | 1.11% | Hold | 100,000 | $122.58 | $12M | — | — |
| CABA - Cabaletta Bio | 1.09% | Add +180.0% | 3,863,800 | $3.11 | $12M | +2,483,800 | +$8M |
| QTTB - Q32 Bio | 1.07% | Reduce −25.9% | 931,000 | $12.74 | $12M | −325,228 | +$4M |
| ANNX - Annexon | 0.89% | Reduce −26.5% | 1,714,451 | $5.71 | $10M | −617,310 | −$3M |
| VSTM - Verastem | 0.62% | New | 1,800,000 | $3.82 | $7M | +1,800,000 | +$7M |
| ZNTL - Zentalis Pharmaceuticals | 0.62% | Hold | 1,412,656 | $4.85 | $7M | — | — |
| RLMD - Relmada Therapeutics | 0.59% | Hold | 935,000 | $6.92 | $6M | — | — |
| OCUL - Ocular Therapeutix | 0.53% | Hold | 600,000 | $9.82 | $6M | — | — |
| TRVI - Trevi Therapeutics | 0.52% | Reduce −10.2% | 310,000 | $18.65 | $6M | −35,100 | +$2M |
| BBOT — | 0.48% | Add +1213.8% | 700,000 | $7.62 | $5M | +646,718 | +$5M |
| LYEL - Lyell Immunopharma | 0.44% | Add +334.9% | 344,025 | $14.05 | $5M | +264,928 | +$3M |
| IRD - Opus Genetics | 0.42% | Add +0.4% | 1,125,000 | $4.11 | $5M | +5,000 | +$2M |
| FDMT — | 0.40% | Add +197.8% | 334,437 | $13.30 | $4M | +222,146 | +$3M |
| INTC - Intellia Therapeutics | 0.38% | Add +2.0% | 250,000 | $16.92 | $4M | +5,000 | +$1M |
| VYGR - Voyager Therapeutics | 0.38% | Add +3.0% | 1,185,000 | $3.50 | $4M | +35,000 | −$292K |
| BDSX - Biodesix | 0.37% | Reduce −24.4% | 180,000 | $22.55 | $4M | −58,047 | +$607K |
| RCKT - Rocket Pharmaceuticals | 0.31% | Add +4.7% | 1,000,000 | $3.42 | $3M | +45,000 | +$1K |
| JBIO - Jade Biosciences | 0.29% | Reduce −66.1% | 145,000 | $22.22 | $3M | −282,608 | −$3M |
| SNWV - Sanuwave Health | 0.28% | Reduce −68.8% | 306,140 | $10.00 | $3M | −675,127 | −$14M |
| FBIO - Fortress Biotech | 0.25% | Reduce −14.6% | 890,000 | $3.06 | $3M | −152,000 | −$184K |
| DERM - Journey Med | 0.22% | Reduce −63.5% | 350,000 | $7.08 | $2M | −610,000 | −$2M |
| PHAT - Phathom Pharmaceuticals | 0.18% | New | 185,589 | $10.85 | $2M | +185,589 | +$2M |
| INBX - Inhibrx Biosciences | 0.17% | New | 20,291 | $94.75 | $2M | +20,291 | +$2M |
| ENTA - Enanta Pharmaceuticals | 0.17% | Hold | 125,000 | $14.58 | $2M | — | — |
| COAG - Hemab Therapeutics | 0.16% | New | 47,652 | $36.73 | $2M | +47,652 | +$2M |
| TRAX - First Tracks | 0.12% | New | 65,000 | $20.12 | $1M | +65,000 | +$1M |
| CGON - Cg Oncology | 0.11% | Reduce −81.2% | 17,789 | $71.05 | $1M | −77,011 | −$5M |
| BHVN - Biohaven | 0.10% | New | 77,915 | $14.88 | $1M | +77,915 | +$1M |
| AVIR - Atea Pharmaceuticals | 0.10% | Reduce −27.2% | 235,000 | $4.65 | $1M | −87,600 | −$643K |
| KTTA - Pasithea Therapeutics | 0.10% | New | 2,050,000 | $0.5154 | $1M | +2,050,000 | +$1M |
| ADCT - Adc Therapeutics SA | 0.07% | New | 700,000 | $1.07 | $749K | +700,000 | +$749K |
| OKYO - Okyo Pharma | 0.05% | New | 375,204 | $1.50 | $563K | +375,204 | +$563K |
| PTN - Palatin Technologies | 0.02% | New | 20,500 | $10.79 | $221K | +20,500 | +$221K |
| ADGM - Adagio Med | 0.00% | Hold | 18,444 | $0.7240 | $13K | — | — |
Showing top 50 of 58 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2026 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| CATX - Perspective Therapeutics | 2.57% | Exit | 0 | $4.17 | $19M | −4,675,000 | −$19M |
| AH30 - Assertio | 0.67% | Exit | 0 | $19.06 | $5M | −265,707 | −$5M |
| STRO - Sutro Biopharma | 0.63% | Exit | 0 | $24.91 | $5M | −190,671 | −$5M |
| TECX - Tectonic Therapeutic | 0.50% | Exit | 0 | $30.91 | $4M | −123,000 | −$4M |
| RIGL - Rigel Pharmaceuticals | 0.25% | Exit | 0 | $27.04 | $2M | −70,000 | −$2M |
| NXTC - Nextcure | 0.20% | Exit | 0 | $10.68 | $2M | −141,181 | −$2M |
| PLX - Protalix Biotherapeutics | 0.10% | Exit | 0 | $2.17 | $738K | −340,000 | −$738K |
| LBRX - Lb Pharmaceuticals | 0.05% | Exit | 0 | $24.68 | $358K | −14,506 | −$358K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2